Piper Sandler maintains Replimune Group at Overweight, raises price target to $27 from $14
Piper Sandler kept its Overweight rating on Replimune Group and raised its price target to $27 from $14, suggesting a 23.3% upside from the Nov 13 close of $21.89.

